Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but have side effects.
Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects.
Conclusion: In this review, we highlighted the metabolism of dopamine, different types of dopamine agonists with their properties and possible side effects.
Keywords: Neurodegenerative disease, dopamine, agonists, metabolism, neurotransmitters, central nervous system.
Current Drug Targets
Title:Dopamine: Agonists and Neurodegenerative Disorders
Volume: 19 Issue: 14
Author(s): Saba Khanam and Yasir Hasan Siddique*
Affiliation:
- Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, Uttar Pradesh 202002,India
Keywords: Neurodegenerative disease, dopamine, agonists, metabolism, neurotransmitters, central nervous system.
Abstract: Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc). Despite many researches, there is still no cure for this disease. Levodopa is the first line treatment of PD, but the long term use of it leads to motor impairments and dyskinesias. The dopamine agonists are the preferred choice for the treatment of PD. They are neuroprotective in nature but have side effects.
Objective: Our aim was to review the work that has been carried out on dopamine agonists and the future possibilities to reduce their side effects.
Conclusion: In this review, we highlighted the metabolism of dopamine, different types of dopamine agonists with their properties and possible side effects.
Export Options
About this article
Cite this article as:
Khanam Saba and Siddique Hasan Yasir*, Dopamine: Agonists and Neurodegenerative Disorders, Current Drug Targets 2018; 19 (14) . https://dx.doi.org/10.2174/1389450118666171117124340
DOI https://dx.doi.org/10.2174/1389450118666171117124340 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Association of the <i>MAOB</i> rs1799836 Single Nucleotide Polymorphism and <i>APOE</i> ε4 Allele in Alzheimer’s Disease
Current Alzheimer Research Genetic Anomalies of the Respiratory Tract
Current Respiratory Medicine Reviews Molecular Recognisation of 3a, 4-Dihydro-3-H-Indeno [1, 2-C] Pyrazole-2- Carboxamide/Carbothioamide Anticonvulsant Analogues Towards GABA-Aminotransferase- An in Silico Approach
Central Nervous System Agents in Medicinal Chemistry Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors
CNS & Neurological Disorders - Drug Targets Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder
Current Psychopharmacology Recent Progress in Anticonvulsant Drug Research: Strategies for Anticonvulsant Drug Development and Applications of Antiepileptic Drugs for Non-Epileptic Central Nervous System Disorders
Current Topics in Medicinal Chemistry Changing Faces of Transcriptional Regulation Reflected by Zic3
Current Genomics Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Anti-Inflammatory Agents in Parkinsons Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Impulse Control Disorders in Parkinson’s Disease: A Review
Current Psychiatry Reviews Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics
Current Molecular Medicine Functional Imaging as a Tool to Investigate the Relationship between Genetic Variation and Response to Treatment with Antipsychotics
Current Pharmaceutical Design